Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis

Journal of Pathology

Volumn 226, Issue 4, 2012, Pages 609-618

  Booth, Adam J ^a   Wood, Sherri C ^a   Cornett, Ashley M ^a   Dreffs, Alyssa A ^a   Lu, Guanyi ^a   Muro, Andrés F ^b   White, Eric S ^a   Bishop, D Keith ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

allograft; fibronectin; fibrosis; immune response; transplantation

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; EXTRA DOMAIN A CONTAINING CELLULAR FIBRONECTIN; FIBRONECTIN; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINEAGE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FIBROGENESIS; GRAFT SURVIVAL; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; WILD TYPE; WOUND HEALING;

ACUTE DISEASE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; FIBROSIS; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; SPLEEN; TRANSPLANTATION, HOMOLOGOUS; VENTRICULAR REMODELING;

EID: 84856738358     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3010     Document Type: Article

References (51)

1. Hornick P, Rose M,. Chronic rejection in the heart. Methods Mol Biol 2006; 333: 131-144.
2. Mehra MR,. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006; 6: 1248-1256. (Pubitemid 44030306)
3. Torre-Amione G,. Cardiac allograft hypertrophy: a new target for therapy, a surrogate marker for survival? Am J Transplant 2009; 9: 7-8.
4. Coito AJ, Onodera K, Kato H, et al., Fibronectin-mononuclear cell interactions regulate type 1 helper T cell cytokine network in tolerant transplant recipients. Am J Pathol 2000; 157: 1207-1218.
5. Adair-Kirk TL, Senior RM,. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol 2008; 40: 1101-1110.
6. Korpos E, Wu C, Song J, et al., Role of the extracellular matrix in lymphocyte migration. Cell Tissue Res 2010; 339: 47-57.
7. Chan SY, DeBruyne LA, Goodman RE, et al., In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995; 59: 1155-1161.
8. Piccotti JR, Chan SY, Goodman RE, et al., IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol 1996; 157: 1951-1957. (Pubitemid 126449668)
9. Libby P, Pober JS,. Chronic rejection. Immunity 2001; 14: 387-397. (Pubitemid 32441591)
10. Boehler A, Kesten S, Weder W, et al., Bronchiolitis obliterans after lung transplantation: a review. Chest 1998; 114: 1411-1426. (Pubitemid 28527420)
11. Mannon RB,. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 2006; 6: 867-875. (Pubitemid 44356636)
12. Csencsits K, Wood SC, Lu G, et al., Transforming growth factor-beta1 gene transfer is associated with the development of regulatory cells. Am J Transplant 2005; 5: 2378-2384.
13. Chan SY, Goodman RE, Szmuszkovicz JR, et al., DNA-liposome versus adenoviral mediated gene transfer of transforming growth factor beta1 in vascularized cardiac allografts: differential sensitivity of CD4+ and CD8+ T cells to transforming growth factor beta1. Transplantation 2000; 70: 1292-1301.
14. Booth AJ, Csencsits-Smith K, Wood SC, et al., Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010; 10: 220-230.
15. Csencsits K, Wood SC, Lu G, et al., Transforming growth factor beta-induced connective tissue growth factor and chronic allograft rejection. Am J Transplant 2006; 6: 959-966. (Pubitemid 44356645)
16. Muro AF, Moretti FA, Moore BB, et al., An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 638-645. (Pubitemid 351442171)
17. Broekelmann TJ, Limper AH, Colby TV, et al., Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991; 88: 6642-6646. (Pubitemid 21915005)
18. Kuhn C 3rd, Boldt J, King TE Jr, et al., An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140: 1693-1703. (Pubitemid 20041056)
19. White ES, Baralle FE, Muro AF,. New insights into form and function of fibronectin splice variants. J Pathol 2008; 216: 1-14.
20. Serini G, Bochaton-Piallat ML, Ropraz P, et al., The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 1998; 142: 873-881. (Pubitemid 28381502)
21. Okamura Y, Watari M, Jerud ES, et al., The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 10229-10233.
22. Coito AJ, Brown LF, Peters JH, et al., Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 1997; 150: 1757-1772. (Pubitemid 27193822)
23. Franz M, Berndt A, Grun K, et al., Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection. J Heart Lung Transplant 2011; 30: 86-94.
24. Franz M, Brehm BR, Richter P, et al., Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. J Mol Histol 2010; 41: 39-50.
25. Franz M, Grun K, Richter P, et al., Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol 2010; 134: 503-517.
26. Muro AF, Chauhan AK, Gajovic S, et al., Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol 2003; 162: 149-160. (Pubitemid 36859542)
27. White ES, Atrasz RG, Hu B, et al., Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006; 173: 112-121. (Pubitemid 43069796)
28. Corry RJ, Winn HJ, Russell PS,. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343-350.
29. Diaz JA, Booth AJ, Lu G, et al., Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009; 9: 1773-1783.
30. Davis LS, Oppenheimer-Marks N, Bednarczyk JL, et al., Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J Immunol 1990; 145: 785-793. (Pubitemid 20231266)
31. Utsumi K, Sawada M, Narumiya S, et al., Adhesion of immature thymocytes to thymic stromal cells through fibronectin molecules and its significance for the induction of thymocyte differentiation. Proc Natl Acad Sci U S A 1991; 88: 5685-5689. (Pubitemid 21914810)
32. Saito S, Yamaji N, Yasunaga K, et al., The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism. J Biol Chem 1999; 274: 30756-30763.
33. Nemzek JA, Bolgos GL, Williams BA, et al., Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflamm Res 2001; 50: 523-527. (Pubitemid 32999716)
34. Sandig H, McDonald J, Gilmour J, et al., Fibronectin is a TH1-specific molecule in human subjects. J Allergy Clin Immunol 2009; 124:528-535.
35. Arslan F, Smeets MB, Riem Vis PW, et al., Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res 2011; 108: 582-592.
36. Hernnas J, Nettelbladt O, Bjermer L, et al., Alveolar accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary fibrosis in the rat. Eur Respir J 1992; 5: 404-410.
37. Jarnagin WR, Rockey DC, Koteliansky VE, et al., Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127: 2037-2048.
38. Bishop DK, Li W, Chan SY, et al., Helper T lymphocyte unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Implications for cellular and humoral responses. Transplantation 1994; 58: 576-584. (Pubitemid 24289849)
39. Piccotti JR, Li K, Chan SY, et al., Cytokine regulation of chronic cardiac allograft rejection: evidence against a role for Th1 in the disease process. Transplantation 1999; 67: 1548-1555. (Pubitemid 29315676)
40. Booth AJ, Bishop DK,. TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. Immunotherapy 2010; 2: 511-520.
41. Raichlin E, Villarraga HR, Chandrasekaran K, et al., Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. Am J Transplant 2009; 9: 132-139.
42. Wood SC, Lu G, Burrell BE, et al., Transplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells. Am J Transplant 2008; 8: 2037-2048.
43. Moretti FA, Chauhan AK, Iaconcig A, et al., A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. J Biol Chem 2007; 282: 28057-28062. (Pubitemid 47529518)
44. Borsi L, Castellani P, Risso AM, et al., Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 1990; 261: 175-178. (Pubitemid 20064800)
45. Thickett DR, Poole AR, Millar AB,. The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 27-33. (Pubitemid 32280534)
46. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, et al., Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 1985; 4: 1755-1759.
47. Peters JH, Sporn LA, Ginsberg MH, et al., Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type III homology (ED1). Blood 1990; 75: 1801-1808. (Pubitemid 20161493)
48. Dubin D, Peters JH, Brown LF, et al., Balloon catheterization induced arterial expression of embryonic fibronectins. Arterioscler Thromb Vasc Biol 1995; 15: 1958-1967.
49. Peters JH, Ginsberg MH, Bohl BP, et al., Intravascular release of intact cellular fibronectin during oxidant-induced injury of the in vitro perfused rabbit lung. J Clin Invest 1986; 78: 1596-1603. (Pubitemid 17219523)
50. Thannickal VJ, Lee DY, White ES, et al., Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003; 278: 12384-12389. (Pubitemid 36800223)
51. Kohan M, Muro AF, White ES, et al., EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J 2010; 24: 4503-4512.